SCYNEXIS announced a private placement that will raise $40 million in gross proceeds from the sale of 34.75 million shares of common stock at $0.92 per share, plus pre‑funded and common warrants. The deal also provides up to $52.2 million in additional proceeds if the warrants are fully exercised, giving the company a potential total of $92.2 million in capital.
The placement was executed on March 30 2026, with the announcement made on March 31. The offering includes 108,695 common shares and accompanying warrants sold to CEO Dr. David Angulo, underscoring management confidence. The warrants expire on the earlier of the fifth anniversary of closing or 30 days after the public release of Phase 2 data for SCY‑770.
SCYNEXIS will use the net proceeds for working capital and general corporate purposes. Combined with its $56.3 million in cash, cash equivalents, and marketable securities as of December 31 2025, the company now has a runway that extends through mid‑2029, well beyond the two‑year horizon it had before the raise.
The financing supports the company’s strategic shift toward rare‑disease therapeutics, particularly the SCY‑770 program for autosomal dominant polycystic kidney disease, which has orphan drug designation and is slated to enter a Phase 2 proof‑of‑concept study in Q4 2026. The additional capital also backs the ongoing development of SCY‑247 and the partnership with GSK for BREXAFEMME.
While the warrants could dilute the share count if exercised, the current exercise price of $1.20 is above the stock’s trading price, and the warrants are subject to stockholder approval within 90 days. The company’s strong current ratio of 7.04 and lack of debt further cushion the dilution risk.
Investors in the placement include Great Point Partners, Squadron Capital Management, Adage Capital Management, and Propel Bio Partners, indicating confidence from a mix of institutional and accredited investors.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.